Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

There is a great unmet medical need for development of molecularly characterizing modalities to assist in the complex classification of rare kidney cancers, some of which are diagnosed as unclassified renal cell carcinoma (unclassified RCC) due to complex histology. Here we show utility of the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Whereas whole genome sequencing (WGS) of 52 rare kidney cancers identifies very few clinically significant variants in a subset of cases, unsupervised clustering results of RNA-seq data from 219 renal tumors including 140 rare kidney cancers are largely consistent with the histological classification based on WHO2022 classification. Additionally, the comparative transcriptome atlas may provide an opportunity to define the molecular characteristics of unclassified RCC and might predict patient outcome. These findings support the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2025-11-24
DOI
https://doi.org/10.1038/s41467-025-65303-z
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

Mitsuko Furuya, Shinji Ohtake, Yukihide Momozawa, Hajime Sasagawa et al.
Nature Communications
Renal cell carcinoma treatment
article

Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

Mitsuko Furuya, Shinji Ohtake, Yukihide Momozawa, Hajime Sasagawa, Hwajin Lee, Kentaro Muraoka, Takehiko Ogawa, Kazuhiro Maejima, Takashi Kawahara, Tomonori Habuchi, Yuji Miura, Haruka Hamanoue, Yusuke Ito, Mitsuru Komeya, Kazuyuki Numakura, Todd A. Johnson, Shota Sasagawa, Brian Shuch, Shigekatsu Maekawa, Toyonori Tsuzuki, Yoji Nagashima, Hiroki Ito, Go Kimura, Wataru Obara, Hisashi Hasumi, Yasuhiro Iribe, Ryosuke Jikuya, Kazuhide Makiyama, Akira Nishiyama, Go Noguchi, Toshio Suda, Masahiro Yao, Tomoyuki Tatenuma, Masaya Baba, Taku Mitome, Kota Aomori, Daiki Ueno, Erika Muraoka, Takanori Hasegawa, Yuki Kanazashi, Sachi Kawaura, Hidewaki Nakagawa, Ikuma Kato, Woojeung Song, Laura S. Schmidt, Christopher J. Ricketts, Seiya Imoto, Tomohiko Tamura, Satoshi Fujii, Tatsuhiko Kodama, W. Marston Linehan, Hiroji Uemura, Hirotaka Nagasaka
article en

Abstract

There is a great unmet medical need for development of molecularly characterizing modalities to assist in the complex classification of rare kidney cancers, some of which are diagnosed as unclassified renal cell carcinoma (unclassified RCC) due to complex histology. Here we show utility of the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Whereas whole genome sequencing (WGS) of 52 rare kidney cancers identifies very few clinically significant variants in a subset of cases, unsupervised clustering results of RNA-seq data from 219 renal tumors including 140 rare kidney cancers are largely consistent with the histological classification based on WHO2022 classification. Additionally, the comparative transcriptome atlas may provide an opportunity to define the molecular characteristics of unclassified RCC and might predict patient outcome. These findings support the comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers.

Nature CommunicationsVol. 16(1)
National Institutes of Health (US), Iwate Medical University (JP), Akita University (JP), UCLA Health (US), Kyung Hee University (KR), Tokyo Metropolitan Institute of Medical Science (JP), Aichi Medical University Hospital (JP), Frederick National Laboratory for Cancer Research (US), Tokyo Women's Medical University (JP), The Cancer Institute Hospital (JP), National Cancer Institute (US), Hokkaido University Hospital (JP), Center for Cancer Research (US), RIKEN Center for Integrative Medical Sciences (JP), Japanese Foundation For Cancer Research (JP), The University of Tokyo (JP), Nippon Medical School (JP), Yokohama City University (JP), Kumamoto University (JP)
U.S. Department of Health and Human Services, Frederick National Laboratory for Cancer Research, Nippon Shinyaku, National Institutes of Health, Japan Society for the Promotion of Science, National Cancer Institute
Openalex Percentile: Top 49%
Renal cell carcinoma treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.